The synthetic lethality approach based on dinaciclib in combination with taselisib impairs CR-CSphCs viability and clonogenic capacity, with a concomitant reduction of Myc and PI3K/AKT pathway activity in the presence of TME cytokines, in line with the stabilization of tumor growth in mouse avatars. The gene discussed is MYC; the disease is neoplasm.